LU90902I2 - Eletriptan et ses sels pharmaceutiquement acceptables y compris le sel d'hydrobromure - Google Patents

Eletriptan et ses sels pharmaceutiquement acceptables y compris le sel d'hydrobromure

Info

Publication number
LU90902I2
LU90902I2 LU90902C LU90902C LU90902I2 LU 90902 I2 LU90902 I2 LU 90902I2 LU 90902 C LU90902 C LU 90902C LU 90902 C LU90902 C LU 90902C LU 90902 I2 LU90902 I2 LU 90902I2
Authority
LU
Luxembourg
Prior art keywords
aryl
alkyl
hydrogen
nr5r6
compounds
Prior art date
Application number
LU90902C
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24393510&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90902(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of LU90902I2 publication Critical patent/LU90902I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU90902C 1990-10-15 2002-03-20 Eletriptan et ses sels pharmaceutiquement acceptables y compris le sel d'hydrobromure LU90902I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59792890A 1990-10-15 1990-10-15
PCT/US1991/007194 WO1992006973A1 (fr) 1990-10-15 1991-10-08 Derives d'indole

Publications (1)

Publication Number Publication Date
LU90902I2 true LU90902I2 (fr) 2002-06-26

Family

ID=24393510

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90902C LU90902I2 (fr) 1990-10-15 2002-03-20 Eletriptan et ses sels pharmaceutiquement acceptables y compris le sel d'hydrobromure

Country Status (33)

Country Link
EP (1) EP0592438B1 (fr)
JP (2) JP2575272B2 (fr)
KR (1) KR0179053B1 (fr)
CN (1) CN1039322C (fr)
AT (1) ATE157361T1 (fr)
AU (1) AU651637B2 (fr)
BG (1) BG61975B1 (fr)
BR (2) BR9106978A (fr)
CA (1) CA2091562C (fr)
DE (3) DE69127468T2 (fr)
DK (1) DK0592438T5 (fr)
EG (1) EG20224A (fr)
ES (1) ES2104733T3 (fr)
FI (1) FI105812B (fr)
GR (1) GR3025087T3 (fr)
HU (2) HUT64326A (fr)
IE (1) IE913555A1 (fr)
IL (3) IL99701A (fr)
LU (1) LU90902I2 (fr)
MX (1) MX9101606A (fr)
MY (1) MY111683A (fr)
NL (1) NL300070I2 (fr)
NO (3) NO305121B1 (fr)
NZ (2) NZ240217A (fr)
OA (1) OA09874A (fr)
PL (3) PL170330B1 (fr)
PT (1) PT99218B (fr)
RO (1) RO111767B1 (fr)
RU (1) RU2095360C1 (fr)
SG (1) SG54270A1 (fr)
WO (1) WO1992006973A1 (fr)
YU (1) YU48088B (fr)
ZA (1) ZA918156B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
UA41297C2 (uk) * 1991-11-25 2001-09-17 Пфайзер, Інк. Похідні індолу, фармацевтична композиція і спосіб лікування
TW288010B (fr) * 1992-03-05 1996-10-11 Pfizer
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
DE69307875T2 (de) * 1992-04-10 1997-05-22 Pfizer Acylaminoindolderivate als 5-ht1 agonisten
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
TW251284B (fr) * 1992-11-02 1995-07-11 Pfizer
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271352B (it) * 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
CA2157397C (fr) * 1993-04-22 1999-07-06 Martin James Wythes Derives de l'indole utilises comme agonistes de type 5-ht1, pour le traitement de la migraine
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
ES2070772B1 (es) * 1993-08-09 1996-02-16 Pfizer Derivados de acilaminoindol
KR100191973B1 (ko) * 1993-08-31 1999-06-15 디. 제이. 우드, 스피겔 알렌 제이 5-아릴인돌 유도체
EP0775131A2 (fr) * 1994-08-03 1997-05-28 ASTA Medica Aktiengesellschaft Derives d'indol, d'indazol, de pyridopyrrol et de pyridopyrazol a effet antiasthmatique, antiallergique, anti-inflammatoire et immunomodulateur
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
WO1996011923A1 (fr) * 1994-10-12 1996-04-25 Pfizer Limited Derive indole destine au traitement de la migraine
GB9420529D0 (en) * 1994-10-12 1994-11-30 Pfizer Ltd Indoles
AU726560B2 (en) * 1994-10-12 2000-11-09 Pfizer Research And Development Company, N.V./S.A. Use of indole derivatives for the treatment of various diseases
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
MX9706969A (es) * 1995-03-20 1997-11-29 Lilly Co Eli 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
US5945118A (en) * 1995-09-29 1999-08-31 Pfizer Inc Indole derivative for the treatment of migraine
GB9714383D0 (en) * 1997-07-08 1997-09-10 Pfizer Ltd Improved process
AU3170099A (en) * 1998-04-16 1999-11-08 Yamanouchi Pharmaceutical Co., Ltd. Remedies for obesity
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP2000336074A (ja) 1999-03-24 2000-12-05 Sumitomo Chem Co Ltd ［２−（アリールスルホニル）エテニル］ベンゼン誘導体の製造方法
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US6515141B1 (en) * 1999-08-26 2003-02-04 Fujisawa Pharmaceutical Co., Ltd. Process for the preparation of indole derivatives or salts thereof
GB9923314D0 (en) * 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
FR2799463B1 (fr) * 1999-10-12 2004-04-16 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et ces compositions pharmaceutiques qui les contiennent
US20030166704A1 (en) 2000-12-20 2003-09-04 Pfizer Inc. New process
GB0031094D0 (en) * 2000-12-20 2001-01-31 Pfizer Ltd New Process
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
EP3168218B1 (fr) 2001-08-15 2018-11-14 Pharmacia & Upjohn Company LLC Un cristal comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide pour utilisation comme un médicament
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
EP1644004A4 (fr) 2003-06-20 2010-10-06 Ronald Aung-Din Therapie locale pour le traitement des migraines, des claquages musculaires, des spasmes musculaires, de la spasticite et d'etats apparentes
KR20080016648A (ko) 2005-06-15 2008-02-21 화이자 리미티드 기생충 방제용 치환된 아릴피라졸
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
WO2006079999A2 (fr) * 2006-04-09 2006-08-03 Barth Frederik H Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
WO2010005507A1 (fr) 2008-06-30 2010-01-14 Afgin Pharma, Llc Traitement neuro-affectif régional topique
EP2149573A1 (fr) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Composé de sulfamide d'indole substituée, leur préparation et utilisation en tant que médicament
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (fr) 2009-06-25 2011-01-13 Matrix Laboratories Ltd Procédé amélioré d'élaboration d'élétriptane et son sel correspondant
WO2011024039A1 (fr) * 2009-08-25 2011-03-03 Ramesh Babu Potluri Synthèse de nouveaux dérivés 5-(2-(phénylsulfonyl)éthyl)-1h-indole
WO2011089614A1 (fr) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited Procédé de préparation de bromhydrate d'élétriptan ayant une forme α
CN102606426B (zh) * 2012-03-02 2014-05-21 王仲彦 踏步健身发电装置
WO2014063752A1 (fr) 2012-10-26 2014-05-01 Synthon Bv Procédé de production de la forme cristalline alpha du bromhydrure d'élétriptan
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
CN103408535B (zh) * 2013-08-13 2016-03-02 张家港威胜生物医药有限公司 一种依来曲普坦中间体-5-溴-3-(n-甲基吡咯啉-2-基甲基)-1h-吲哚合成工艺
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
BR112017018944A2 (pt) 2015-03-02 2018-05-15 Afgin Pharma Llc método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s)
JP2019502761A (ja) 2016-01-21 2019-01-31 ラボラトリオス レヴィ エセエレ （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
TR201616365A1 (tr) 2016-11-14 2018-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deksketoprofen ve eletri̇ptanin oral farmasöti̇k kompozi̇syonlari
TR201619983A2 (tr) 2016-12-29 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari
KR102129947B1 (ko) 2018-06-08 2020-07-03 김종창 콘크리트 타설을 위한 입체형 와이어 메쉬
EP3766483A1 (fr) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Composition de poudre orodispersible comprenant un triptane
WO2021148868A1 (fr) 2020-01-22 2021-07-29 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Bromhydrate d'élétriptan destiné au traitement d'une lésion médullaire et à l'amélioration de la fonction locomotrice
WO2023150547A2 (fr) * 2022-02-01 2023-08-10 Caamtech, Inc. Composés psychédéliques et leurs utilisations thérapeutiques

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL74527C (fr) *
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
NO305121B1 (no) 1999-04-06
JP2575272B2 (ja) 1997-01-22
EG20224A (en) 1997-12-31
HU225055B1 (en) 2006-05-29
NO2001019I1 (no) 2001-12-03
DE69127468T2 (de) 1998-01-02
DE69127468D1 (de) 1997-10-02
CN1039322C (zh) 1998-07-29
AU8950491A (en) 1992-05-20
DK0592438T3 (da) 1997-09-29
BG97632A (bg) 1994-03-31
AU651637B2 (en) 1994-07-28
NO931378L (no) 1993-04-14
CN1062529A (zh) 1992-07-08
BR9106978A (pt) 1993-09-28
OA09874A (en) 1994-09-15
ATE157361T1 (de) 1997-09-15
BG61975B1 (bg) 1998-11-30
FI931667A (fi) 1993-04-14
DE9190141U1 (fr) 1993-07-15
PT99218A (pt) 1992-09-30
ZA918156B (en) 1993-04-14
IL115117A0 (en) 1995-12-08
JPH093063A (ja) 1997-01-07
IL99701A (en) 1996-10-31
HU9301098D0 (en) 1993-07-28
MX9101606A (es) 1992-06-05
FI105812B (fi) 2000-10-13
RO111767B1 (ro) 1997-01-30
NZ240217A (en) 1995-05-26
JP2677777B2 (ja) 1997-11-17
RU2095360C1 (ru) 1997-11-10
PL168919B1 (pl) 1996-05-31
FI931667A0 (fi) 1993-04-14
GR3025087T3 (en) 1998-01-30
PL170330B1 (pl) 1996-11-29
SG54270A1 (en) 1998-11-16
IL99701A0 (en) 1992-08-18
DK0592438T5 (da) 1999-12-06
NZ270675A (en) 1997-07-27
NL300070I2 (nl) 2002-03-01
MY111683A (en) 2000-11-30
YU165391A (sh) 1994-01-20
IL115117A (en) 1996-11-14
PT99218B (pt) 1999-04-30
NO931378D0 (no) 1993-04-14
BR1100080A (pt) 2000-06-06
NO985607D0 (no) 1998-12-01
JPH05507288A (ja) 1993-10-21
NO985607L (no) 1998-12-01
IE913555A1 (en) 1992-04-22
ES2104733T3 (es) 1997-10-16
CA2091562A1 (fr) 1992-04-16
DE10299004I1 (de) 2002-05-08
PL169987B1 (en) 1996-09-30
EP0592438A1 (fr) 1994-04-20
DE10299004I2 (de) 2006-03-16
HUT64326A (en) 1993-12-28
NL300070I1 (nl) 2002-02-01
EP0592438B1 (fr) 1997-08-27
KR0179053B1 (ko) 1999-03-20
YU48088B (sh) 1997-01-08
CA2091562C (fr) 2001-03-27
WO1992006973A1 (fr) 1992-04-30

Similar Documents

Publication Publication Date Title
LU90902I2 (fr) Eletriptan et ses sels pharmaceutiquement acceptables y compris le sel d'hydrobromure
NO960818L (no) 5-Arylindol-derivater
MY108909A (en) Indole derivatives